Visual Outcomes After Vivity Toric IOL Implantation

NATerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions
Refractive Assessment
Interventions
OTHER

Procedure: Vivity Toric IOL

The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.

Trial Locations (1)

81501

Icon Eye Care, Grand Junction

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alcon Research

INDUSTRY

collaborator

Icon Eye Care

OTHER

lead

EVP Eye Care

OTHER